Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis

P. Demoly (1, 2) , J. Kleine-Tebbe , D. Rehm

1 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
2 Département pneumologie et addictologie [Montpellier]

Treatment with SQ (standardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild AR day (from 16% [placebo] to 34% [SQ house dust mite sublingual tablet]).

Mots clés: SQ HDM SLIT-tablet; allergic rhinitis; allergy immunotherapy; clinical relevance; house dust mite

Domaines: Allergologie

P. Demoly, J. Kleine-Tebbe, D. Rehm. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis. Allergy, 2017, 72 (10), pp.1576 - 1578. ⟨10.1111/all.13155⟩. ⟨hal-01777831⟩